risks of glp 1 inhibitors A Balancing Act: Weighing the Benefits GLP-1s GLP-1 use tied to lower

Comparative efficacy and safety of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity or overweight: a systematic review and network meta-analysis

Glucagon-like Peptide-1 Receptor Agonists and Muscle Mass Effects. Pharmacological Research , vol

The Look AHEAD: Action for Health in Diabetes (Look AHEAD) trial on the longer-term effects of an intensive lifestyle intervention in adults who were overweight/obese with type 2 diabetes showed improvements in diabetes control and complications, depression, physical function and health-related quality of life, sleep apnoea, incontinence, brain structure and healthcare use and costs, with positive impacts on composite indices of multimorbidity, geriatric syndromes and disability-free life-years

GLP-1(3236)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice